Literature DB >> 24211979

Developmental toxicity of doxorubicin hydrochloride in embryo-larval stages of zebrafish.

Can Chang1, Shao Ling Wu, Xin Dong Zhao, Chun Ting Zhao, Yan Hui Li.   

Abstract

Doxorubicin hydrochloride is widely used to treat various types of cancers. Its therapeutic and side effects are well documented. However, the developmental toxicity of doxorubicin has not been previously described. Lethal and sublethal effects on embryo-larval stages of zebrafish in a study of the developmental toxicity of doxorubicin were observed. Zebrafish embryos were exposed to different concentrations (0-100 mg/L) of doxorubicin between 4 and 120 h post fertilization, and zebrafish larvae were exposed to different concentrations (0-200 mg/L) of doxorubicin for 96 h. The markers about the development toxicity of doxorubicin in zebrafish were observed under a stereomicroscope. Higher doxorubicin concentrations mainly caused acute lethal effects, and lower doxorubicin concentrations mainly caused sublethal effects, such as multiple malformations in embryos and larvae. Moreover, with the increase of doxorubicin concentration, the malformation rate increased. The heart rate of embryos was accelerated at lower concentrations of doxorubicin (≤ 10 mg/L) and decelerated at higher concentrations (≥ 25 mg/L). The hatching rate and body length were inhibited at higher concentrations of doxorubicin (≥ 25 mg/L).In conclusion, doxorubicin has serious developmental toxicity and this raises a concern for developmental effects of doxorubicin in clinical practice.

Entities:  

Keywords:  Doxorubicin hydrochloride; developmental toxicity; embryotoxicity; zebrafish

Mesh:

Substances:

Year:  2014        PMID: 24211979     DOI: 10.3233/BME-130885

Source DB:  PubMed          Journal:  Biomed Mater Eng        ISSN: 0959-2989            Impact factor:   1.300


  7 in total

1.  Acute hypoxia elevates arginase 2 and induces polyamine stress response in zebrafish via evolutionarily conserved mechanism.

Authors:  Bodhisattwa Banerjee; Iryna Khrystoforova; Baruh Polis; Inbar Ben Zvi; David Karasik
Journal:  Cell Mol Life Sci       Date:  2021-12-16       Impact factor: 9.261

2.  Nuciferine Attenuates Doxorubicin-Induced Cardiotoxicity: An In Vitro and In Vivo Study.

Authors:  Rajendran Harishkumar; Johnsamuel Godwin Christopher; Rajan Ravindran; Chinnadurai Immanuel Selvaraj
Journal:  Cardiovasc Toxicol       Date:  2021-08-16       Impact factor: 3.231

3.  Varied effects of doxorubicin (DOX) on the corpus luteum of C57BL/6 mice during early pregnancy†.

Authors:  Christian Lee Andersen; Haeyeun Byun; Yuehuan Li; Shuo Xiao; Doris M Miller; Zidao Wang; Suvitha Viswanathan; Jonathan Matthew Hancock; Jaymie Bromfield; Xiaoqin Ye
Journal:  Biol Reprod       Date:  2021-12-20       Impact factor: 4.161

4.  Evaluation of the potential environmental risk from the destination of medicines: an epidemiological and toxicological study.

Authors:  Mariana A R Salgado; Mariana R Salvador; André O Baldoni; Ralph G Thomé; Hélio Batista Santos
Journal:  Daru       Date:  2021-01-19       Impact factor: 3.117

5.  Podocyte developmental defects caused by adriamycin in zebrafish embryos and larvae: a novel model of glomerular damage.

Authors:  Cristina Zennaro; Massimo Mariotti; Michele Carraro; Sara Pasqualetti; Alessandro Corbelli; Silvia Armelloni; Min Li; Masami Ikehata; Milan Clai; Mary Artero; Piergiorgio Messa; Giuliano Boscutti; Maria Pia Rastaldi
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

6.  Reversal of Doxorubicin-Induced Bone Loss and Mineralization by Supplementation of Resveratrol and MitoTEMPO in the Early Development of Sparus aurata.

Authors:  Sunil Poudel; Marisol Izquierdo; Maria Leonor Cancela; Paulo J Gavaia
Journal:  Nutrients       Date:  2022-03-09       Impact factor: 5.717

7.  A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors.

Authors:  Petko Alov; Merilin Al Sharif; Denitsa Aluani; Konstantin Chegaev; Jelena Dinic; Aleksandra Divac Rankov; Miguel X Fernandes; Fabio Fusi; Alfonso T García-Sosa; Risto Juvonen; Magdalena Kondeva-Burdina; José M Padrón; Ilza Pajeva; Tania Pencheva; Adrián Puerta; Hannu Raunio; Chiara Riganti; Ivanka Tsakovska; Virginia Tzankova; Yordan Yordanov; Simona Saponara
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.